Barclays Reiterates “Equal Weight” Rating for Hikma Pharmaceuticals (LON:HIK)

Barclays reaffirmed their equal weight rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note published on Tuesday morning, Marketbeat.com reports. Barclays currently has a GBX 2,000 ($25.13) target price on the stock.

Separately, Berenberg Bank restated a hold rating and set a GBX 2,000 ($25.13) target price on shares of Hikma Pharmaceuticals in a research report on Thursday, April 25th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Hikma Pharmaceuticals currently has an average rating of Moderate Buy and a consensus price target of GBX 2,068.75 ($25.99).

Hikma Pharmaceuticals Price Performance

Shares of HIK stock opened at GBX 1,967 ($24.71) on Tuesday. The firm has a market cap of £4.36 billion, a price-to-earnings ratio of 2,886.76, a PEG ratio of 2.38 and a beta of 0.44. Hikma Pharmaceuticals has a 12 month low of GBX 1,711 ($21.49) and a 12 month high of GBX 2,222 ($27.91). The stock has a 50-day moving average price of GBX 1,877.07 and a 200 day moving average price of GBX 1,862.25. The company has a quick ratio of 1.27, a current ratio of 1.57 and a debt-to-equity ratio of 53.92.

Hikma Pharmaceuticals Increases Dividend

The business also recently announced a dividend, which was paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st were given a dividend of $0.47 per share. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.25. This represents a dividend yield of 1.86%. The ex-dividend date of this dividend was Thursday, March 21st. Hikma Pharmaceuticals’s payout ratio is presently 8,382.35%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.